<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cilostazol is an antiplatelet aggregation inhibitor drug associated with increased cerebral blood flow and <z:mp ids='MP_0001845'>inflammation</z:mp> suppression </plain></SENT>
<SENT sid="1" pm="."><plain>This study evaluated administration of cilostazol to prevent <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> following <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> (SAH) in 50 patients treated surgically from December 2004 to November 2006 </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients, excluding those with Hunt and Kosnik grade 5 or who had undergone late surgery, were classified into two groups: 26 patients who received 200 mg/day cilostazol from postoperative day 1 to day 14 and 24 control patients </plain></SENT>
<SENT sid="3" pm="."><plain>The frequency and the degree of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e>, occurrence of ischemic lesion, and clinical symptoms due to vasospasm were compared between the two groups </plain></SENT>
<SENT sid="4" pm="."><plain>The appearance of severe vasospasm on angiography, persistent symptomatic spasm, and new <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> due to vasospasm demonstrated by neuroimaging were apparently lower in the cilostazol group than in the control group, suggesting that cilostazol may significantly suppress <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> following SAH </plain></SENT>
</text></document>